We targeted the S2 sample with nine crRNAs targeting the most common recurrent sarcoma fusion partners EWSR1, PAX3, PAX7, and SS18. For all samples we performed WGA on 10 ng starting material and subjected 1 μg of WGA-DNA to the enrichment protocol. The gene discussed is PAX3; the disease is sarcoma.